Orphan Reach today confirmed that they have been acquired by Emmes, a global, full-service CRO dedicated to supporting the advancement of public health and biopharmaceutical innovation.

Orphan Reach CEO Thomas Ogorka commented: “Orphan Reach and Emmes share a passion for the research we do, a dedication to the patients in our trials, and successful, long-term collaborations with our clients. I look forward to this new chapter in our history and to further extending our leadership in rare and orphan disease research that leads to new treatment options for these patients.”

The full press release can be read here: https://lnkd.in/dusytEb

-ENDS-

Notes to Editors:

To learn more about Emmes, please visit: https://emmes.com/  

About Orphan Reach: As a Contract Research Organization focused on clinical trials in indications with high unmet medical need, Orphan Reach has built its reputation around delivering patient centric solutions in very challenging scenarios, particularly in rare diseases. The desire of many biotech companies to find a reliable niche CRO partner to drive their clinical development programs in orphan indications has been a major contributor to the Orphan Reach success story.

Today, the company is present in more than 70 countries globally and connected to an ever-growing patient community who are waiting for new therapies with no time to waste.

For further information, please use the following contact details | T: +44 1908 251 480 | E: info@orphan-reach.com |